Analysis of polymorphism in the protease and reverse transcriptase genes of HIV type 1 CRF02-AG subtypes from drug-naive patients from Saint-Etienne, France

Journal of Acquired Immune Deficiency Syndromes

Volumn 42, Issue 4, 2006, Pages 396-404

  Lawrence, Philip ^a   Lutz, Marie France ^a   Saoudin, Henia ^a   Frésard, Anne ^a   Cazorla, Céline ^a   Fascia, Pascal ^a   Pillet, Sylvie ^a   Pozzetto, Bruno ^a,b   Lucht, Frédéric ^a   Bourlet, Thomas ^a  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^b UNIVERSITÉ JEAN MONNET   (France)

Author keywords

CRF02 AG subtype; Drug resistance; Polymorphism

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLONAL VARIATION; CONSENSUS SEQUENCE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; FRANCE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VIRUS GENE; VIRUS ISOLATION; VIRUS LOAD; VIRUS STRAIN;

ADULT; BASE SEQUENCE; DNA PRIMERS; FEMALE; FRANCE; HIV INFECTIONS; HIV PROTEASE; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHYLOGENY; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 33745906830     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000221675.83950.4a     Document Type: Article

References (40)

1. IbNg) from Nigeria. AIDS Res Hum Retroviruses. 1994;10:1755-1757.
2. Ballota C, Facchi G, Violin M, et al. Increasing prevalence of non clade B HIV-1 strains in heterosexual men and women, as monitored by analysis of reverse transcriptase and protease sequences. J Acquir Immune Defic Syndr. 2001;27:499-505.
3. Holguin A, Alvarez A, Soriano V. High prevalence of HIV-1 subtype G and natural polymorphisms at the protease gene among HIV-infected immigrants in Madrid. AIDS. 2002;16:1163-1170.
4. Thomson MM, Najera R. Travel and the introduction of human immunodeficiency virus type 1 non-B subtype genetic forms into Western countries. Clin Infect Dis. 2001;32:1732-1737.
5. Barlow KL, Tatt ID, Cane PA, et al. Recombinant strains of HIV type 1 in the United Kingdom. AIDS Res Hum Retroviruses. 2001;17:467-474.
6. Boni J, Pyra H, Gebhardt M, et al. High frequency of non-B subtypes in newly diagnosed HIV-1 infections in Switzerland. J Acquir Immune Defic Syndr. 1999;22:174-179.
7. Fleury H, Recordon-Pinson P, Caumont A, et al. HIV type 1 diversity in France, 1999-2001: molecular characterization of non-B HIV type 1 subtypes and potential impact on susceptibility to antiretroviral drugs. AIDS Res Hum Retroviruses. 2003;19:41-47.
8. Perez-Alvarez L, Carmona R, Munoz M, et al. High incidence of non-B and recombinant HIV-1 strains in newly diagnosed patients in Galicia, Spain: study of genotypic resistance. Antivir Ther. 2003;8:355-360.
9. Vachot L, Atman-Onal Y, Terrat C, et al. Retrospective study to time the introduction of HIV type 1 non-B subtypes in Lyon, France, using env genes obtained from primary infection samples. AIDS Res Hum Retroviruses. 2004;20:687-691.
10. Granjean M, Bourlet T, Berthelot P, et al. Human immunodeficiency virus type 1 subtypes in a cohort of infected patients, Saint-Etienne, France, from 1984 to 2003. Med Mal Infect. 2005;35:82-87.
11. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA Panel. JAMA. 1998:1984-1991.
12. Schinazi RF, Larder BA, Mellors JW. Mutations in retroviral genes associated with drug resistance. Int Antivir News. 1997:129-142.
13. Fonjungo PN, Mpoundi EN, Torimiro JN, et al. Human immunodeficiency virus type 1 group M protease in Cameroon: genetic diversity and protease inhibitor mutational features. J Clin Microbiol. 2002;40:837-845.
14. Kinomoto M, Appiah-Opong R, Brandful JAM, et al. HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors. Clin Infect Dis. 2005;41:243-251.
15. Vergne L, Peeters M, Mpoudi-Ngole E, et al. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type1 strains: evidence of many minor drug resistance mutations in treatment-naïve patients. J Clin Microbiol. 2000:3919-3925.
16. Kantor R, Katzenstein D, Efron B, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2005;2:325-337.
17. Adje-Toure C, Bile EC, et al. Polymorphism in protease and reverse transcriptase and phenotypic drug resistance of HIV-1 recombinant CRF02 - AG isolates from patients with no prior use of antiretroviral drugs in Abidjan, Côte d'Ivoire. J Acquir Immune Defic Syndr. 2003;34:111-113.
18. Frater AJ, Dunn DT, Beardall AJ, et al. Comparative response of African HIV-1 infected individuals to highly active antiretroviral therapy. AIDS. 2002;16:1139-1146.
19. Konings FA, Zhong P, Agwara M, et al. Protease mutations in HIV-1 non-B strains infecting drug-naive villagers in Cameroon. AIDS Res Hum Retroviruses. 2004;20:105-109.
20. Konings FA, Nyambi PN. V1181 Substitution in the reverse transcriptase gene of HIV1 CRF02 - AG strains infecting drug naive individuals in Cameroon. AIDS Res Hum Retroviruses. 2004;20:673-678.
21. Plantier JC, Le Pogam S, Poisson F, et al. Extent of antigenic diversity in the V3 region of the surface glycoprotein, gp120, of human immunodeficiency virus type 1 group M and consequences for serotyping. J Virol. 1998;72:677-683.
22. Plantier JC, Vergne L, Damond F, et al. Development and evaluation of DNA enzyme immunoassay method for env genotyping of subtypes A through G of human immunodeficiency virus type 1 group M, with discrimination of the circulating recombinant forms CRF01 - AE and CRF02 - AG. J Clin Microbiol. 2002;40:1010-1022.
23. Stuyver L, Wyseur A, Rombout A, et al. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother. 1997;41:284-291.
24. Pasquier C, Millot N, Njouom R, et al. HIV-1 subtyping using phylogenetic analysis of pol gene sequences. J Virol Methods. 2001;94:45-54.
25. Kumar S, Tamura K, Jakobsen IB, et al. MEGA 2: molecular evolutionary genetics analysis software. Bioinformatics. 2001;17:1244-1245.
26. Kimura M. Estimation of evolutionary distances between homologous nucleotide sequences. Proc Natl Acad Sci U S A. 1981;78:454-458.
27. Anonymous. Recommandations du groupe d'experts. Prise en charge thérapeutique des personnes infectées par le VIH. Rapport sous la direction du Pr Delfraissy. 2004. Ed. Flammarion, coll. Médecine Sciences, Paris, France.
28. Laurent C, Bourgeois A, Faye MA, et al. No difference in clinical progression between patients infected with the predominant human immunodeficiency virus type 1 circulating recombinant form (CRF) 02 - AG strain and patients not infected with CRF02 - AG, in Western and West-Central Africa: a four year prospective multicenter study. J Infect Dis. 2002;186:486-492.
29. Toni TD, Recordon-Pinson P, Minga A, et al. Presence of key drug resistance mutations in isolates from untreated patients of Abidjan, Côte d'Ivoire: ANRS 1257 Study. AIDS Res Hum Retroviruses. 2003;19:713-717.
30. Pillay D, Walker AS, Gibb DM, et al. Impact of human immunodeficiency virus type1 subtypes on virologic response and emergence of drug resistance children in the paediatric European network for treatment of AIDS (PENTA) 5 trial. J Infect Dis. 2002;186:617-625.
31. Perno CF, Cozzi-Lepri A, Balotta C, et al. Secondary mutations in protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J Infect Dis. 2001;184:983-991.
32. Velasquez-Campoy A, Todd MJ, Vega S, et al. Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc Natl Acad Sci U S A. 2001;98:6062-6067.
33. Holguin A, Paxinos E, Hertogs K, et al. Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. J Clin Virol. 2004;31:215-220.
34. Brenner B, Routy JP, Quuan Y, et al. Persistance of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS. 2004;18:1653-1660.
35. Delauguerre C, Morand-Joubert L, Chaix ML, et al. Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission. Antivir Ther. 2004;9:415-421.
36. Vergne L, Malonga-Mouellet G, Mistoul I, et al. Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries. J Acquir Immune Defic Syndr. 2002;29:165-168.
37. Adje C, Cheingsong R, Roels TH, et al. High prevalence of genotyping and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire. J Acquir Immune Defic Syndr. 2001;26:501-506.
38. Fleury HJ, Toni TA, Lan NTH, et al. Susceptibility to ARVs of CRF01 - AE, CRF02 - AG and subtype C viruses from naive patients: comparative genotypical and phenotypical data. [abstract 135] XIV International HIV drug resistance workshop: basic principles and clinical implications. Antivir Ther. 2005;10:S148.
39. Frater AJ, Beardall A, Ariyoshi K, et al. Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1 infected African patients. AIDS. 2001;15:1493-1502.
40. Laurent C, Dakhaté N, Gueye N, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS. 2002;16:1363-1370.